AstraZeneca PLC’s PD-L1 checkpoint inhibitor Imfinzi has met with another Phase III failure in head and neck cancer both as a monotherapy and in combination with the company’s investigational product tremelimumab, in a further blow to the combination.
The KESTREL study showed Imfinzi (durvalumab) missed the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?